Platelet-activating factor (PAF) acetylhydrolase has been recognized as an enzyme that inactivates PAF. We developed a convenient and reproducible method for determining human serum PAF acetyihydrolase activity. The assay was based on measurement of 1I4Clacetate produced from 1-O-alkyl-2-1'4C]-acetyl-sn-glycero-3-phosphocholine upon precipitation of the complex of radioactive substrate and albumin with TCA. The apparent Km value of PAF acetylhydrolase (near the physiological concentration of serum protein) was 1.5 X 10-4 M PAF. 32 subjects with serum PAF acetylhydrolase deficiency were found among 816 healthy Japanese adults. The low PAF acetylhydrolase activity in the deficient serum might not be due to the presence of enzyme inhibitor. Both the sensitivity to PAF and the metabolism of PAF in platelets from PAF acetylhydrolase-deficient subjects were almost the same as those of normal subjects. Deficiency in serum PAF acetylhydrolase appeared to be transmitted by autosomal recessive heredity among five Japanese families. Among healthy adults, healthy children, and asthmatic children, who were grouped into five classes on the basis of respiratory symptoms (remission, wheezy, mild, moderate, and severe groups), the probability of PAF acetylhydrolase deficiency was significantly higher in groups with severe symptoms (moderate and severe) (P < 0.01). These results suggest that deficiency of serum PAF acetylhydrolase might be one of the factors leading to severe respiratory symptoms in asthmatic children.
Introduction
Platelet-activating factor ([PAF]'; l-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine [1] [2] [3] [4] ) was originally discovered as a fluid-phase mediator released from antigen-stimulated IgEsensitized basophils, but is now known to be formed in various cells including neutrophils, eosinophils, macrophages, mast cells, and vascular endothelial cells upon chemical or immune stimulation (5) . Sensitized lungs also release PAF when challenged with antigen (6) . This ether phospholipid causes platelet aggregation and degranulation (7-1 1), and is suggested to play an important role in the pathogenesis of anaphylaxis and inflammation (5) . PAF has a wide spectrum of biological activity, not only stimulating platelets (7-1 1), neutrophils (12) , and eosinophils (13, 14) , but also enhancing vascular permeability (15) (16) (17) and inducing hypotension (18, 19) , platelet-dependent bronchoconstriction (20) , smooth muscle contraction (21, 22) , and other alterations (e.g., acute inflammation and edema) in pulmonary dynamics (5) . Because these biological effects are produced at very low concentrations of PAF, in the region of l0-1o-l0-l M, it seems that accumulation of PAF in body fluids and tissues, as in the case of anaphylaxis and endotoxic shock (23) , is highly toxic. It has been reported by Halone et al.
that a dose of PAF as low as 1 gg/kg is lethal in rabbits (24) .
Hence, it is considered that a system to regulate the concentration of PAF (e.g., PAF metabolism into an inactive product) is essential. Before the structure of PAF was identified, it was reported that human and rabbit serum contained an acid-labile factor that inactivated PAF (25, 26) . Later, it was clarified that this PAF-inactivating factor in serum was acetylhydrolase, which hydrolyzes the sn-2-acetyl moiety of PAF to inactive lyso PAF (27, 28) . This enzyme has since been found in the cytosolic fraction of several rat tissues (29, 30) and human blood cells (31) . The current study was focused on acetylhydrolase in human serum and two major findings emerged. First, some Japanese families with serum PAF acetylhydrolase deficiency were found; second, such deficiency or low activity of serum PAF acetylhydrolase was suggested to be correlated with the severity of bronchial asthma in wheezy children. ['4CJAcetyl-PAF (1 -O-alkyl-2-['4C]acetyl-sn-glycero-3-phosphocholine) was synthesized by acetylation of l-O-alkyl-sn-glycero-3-phosphocholine (lyso PAF) with ['4C ]acetic anhydride (Amersham Corp. Japan, Tokyo, Japan) according to the method of Blank et al. (29) . l-O-Alkyl-sn-glycero-3-phosphocholine was prepared by hydrogenation over platinum oxide and alkaline hydrolysis of choline glycerophospholipid from beef heart; the components were 1-O-hexadecyl (78%) and l-O-octadecyl (22%)-sn-glycero-3-phosphocholine (1) . [ '4C]Acetyl-PAF was purified using a silicic acid column and preparative TLC (29 glass test tube at 370C for 10 min unless otherwise indicated. The reaction was stopped by addition of 100 1l of 14% TCA and the mixture was left to stand for 10 min at 00C. To separate the denatured protein, the reaction mixture was centrifuged for 5 min at 2,500 rpm (3,800 g). 100 M1 ofthe supernatant was mixed with 5 ml ofscintillation cocktail (Scintisol EX-H; Dojin Chemical Institute, Kumamoto, Japan) and the radioactivity determined in a liquid scintillation counter (LS602; Aloka Inc., Tokyo, Japan). The control values of released acetic acid were obtained for both free serum and serum heated for 10 min in boiling water. One unit of enzyme activity was defined as that which produced I nmol of acetate per minute at 37°C.
1-O-[3H]
Hexadecyl-2-acetyl-sn-glycero-3-phosphocholine ( (32) . Lipid samples were applied to a precoated Silica gel G TLC plate and run in a solvent system of chloroform/methanol/water (65:35:7, vol/vol/vol). Spots were identified by comigration with authentic standards after exposure with iodine vapor. After spraying with spray reagent (Enhance; New England Nuclear Japan, Tokyo), the radioactivity of each of the spots on the Silica gel G plate was determined with an ultra-high sensitivity TV camera system (ARGUS-100; Hamamatsu Photonics K.K., Hamamatsu, Japan) (33). Subsequently, individual spots were scraped into vials, extracted in 0.2 ml of chloroform/methanol/water (1:2:0.8, vol/vol/vol), and then mixed with 5 ml of scintillation cocktail. The radioactivity was determined in a liquid scintillation counter. Results shown in the tables and figures are the means of duplicate determinations unless otherwise stated. The variations were < 3%.
(b) Bioassay ofserum PAF acetylhydrolase activity. 50 Ml of C160-PAF (2 X 10-9-2 X 10-8 M) suspended in Tyrode buffer (pH 7.2) containing 2.5 mg/ml BSA was incubated with 50 Ml of serum for 5 min at 37°C. 20-,ul aliquots were removed and assayed immediately for platelet-aggregating ability. Rabbit platelets were isolated as previously described (34 (35) . In the remission group were 35 subjects who had experienced neither wheezing nor dyspnea attacks over the previous 2 yr. In the wheezy group were subjects who had experienced wheezing attacks without dyspnea less than four times per year. In the mild group were subjects who had experienced wheezing attacks without dyspnea between five and nine times, or dyspnea attacks without orthopnea less than four times per year. Moderate subjects had experienced wheezing attacks without dyspnea > 10 times, dyspnea attacks without orthopnea between five and nine times, or orthopnea attacks less than four times per year. Severe subjects had experienced dyspnea attacks > 10 times, or orthopnea attacks more than five times per year. All patients in the combined groups of mild, moderate, and severe had displayed the typical clinical characteristics of bronchial asthma. The diagnosis was confirmed hematologically by the total IgE level and by the presence of specific serum IgE antibodies to Dermatophagoides pteronyssinus (radioallergosorbence test [RAST] ; Pharmacia Fine Chemicals Co. Uppsala, Sweden) using mite as the allergen (35) . Of 175 patients, 90 had a serum total IgE value of 300 IU/ml or over, as measured by a paper radioimmunosorbence test, and 85 subjects had levels < 300 IU/ml. Serum total IgE levels in groups with severe symptoms (moderate and severe) were significantly higher than in those with slight symptoms (remission and wheezy). Upon IgE-RAST for measuring the level of specific serum IgE antibodies to Dermatophagoides pteronyssinus, 127 subjects had a RAST score of2 or over, and 48 subjects scored less than 1. The percentages of subjects exhibiting a RAST score of 2 or over in each of the groups (remission, wheezy, mild, moderate, and severe) were 51, 79, 88, 92, and 94, respectively. These results are compatible with those of previous reports on outpatients attending pediatric allergy clinics in Japan. Blood from the patients was collected when asthmatic attacks were absent, unless otherwise stated. In addition, we selected 36 children (6-12 yr old; 18 boys and 18 girls) without any history of wheezing as a control group. The healthy control children had no history of allergic disease. The RAST score was 0, and the total IgE value was < 300 IU/ml. The serum PAF acetylhydrolase activity of 816 healthy adults (20-45 yr old; 408 men and 408 women), who were selected at random from among 1,600 volunteers and had normal values of glutamic oxalic-acetic transaminase, glutamic pyruvic transaminase, alkaline phosphatase, and blood pressure, was also assayed. Serum samples were separated from venous blood by centrifugation after being left to stand for 30 min at room temperature, and kept at -80°C until use.
Results and Discussion
A simple and reproducible method for measuring serum PAF acetylhydrolase activity was developed as follows. ['4C]Acetyl-PAF was incubated with human serum, and then TCA was added to stop the reaction. The TCA-soluble materials were separated from the denatured protein by centrifugation. The acid-soluble fraction after 0-, 5-, and 10-min incubation of ['4C]acetyl-PAF at 0°C with the HCl-treated serum, whose PAF acetylhydrolase had been inactivated by 30-min incubation at pH 1.0 and 37°C and then neutralized, contained 0.98, 1.8, and 2.3% of the radioactivity, respectively. In the case of 1-_-[3H]alkyl-PAF, the acid-soluble fraction after incubation for 10 (Fig. 1) . The correlation coefficient between the results obtained by the TCA precipitation method and the TLC method was 0.993, indicating that it would be possible to determine PAF acetylhydrolase activity from the radioactivity recovered in the supernatant. Fig. 2 shows the kinetics of the time-, serum protein concentration-, and PAF concentration-dependent metabolism. Linearity for up to 15 min of incubation and 3.1 mg of serum protein (-50 ul serum) was observed. As the apparent Km value of human serum PAF acetylhydrolase was 1.5 X I0-' M PAF, the routine enzyme assay used 5 X i0-4 M ['4C]acetyl-PAF and 50 ,d of human serum, unless otherwise stated. The enzyme activity was not affected by EDTA (1-10 mM). The PAF antagonist CV3988 (8 mM) completely inhibited the serum PAF acetylhydrolase activity, indicating that the antagonist competed with PAF for PAF acetylhydrolase. These observations showed that this enzyme activity was not due to phospholipase A2, but mainly to specific PAF acetylhydrolase.
The mean serum PAF acetylhydrolase activities in healthy Japanese adults and healthy children were 1.83±0.75 nmol/ min per 50 u1 serum for 816 subjects (20-45 yr old) and 1.25±0.49 nmol/min per 50 ,1 serum for 21 1 subjects (6-12 yr old; 30 subjects of each age), respectively. Although the mean enzyme activity in healthy adults was higher than that in healthy children, there were no significant differences in the enzyme activity among children of each of the various ages (6-12 yr old). Serum PAF acetylhydrolase activities of healthy subjects showed no change over the course of 1 d, 1 wk, and also over several months (Fig. 3) . There was no statistical difference in enzyme activity between men and women (data not shown).
We found 32 and 8 subjects with PAF acetylhydrolase activity-negative serum among 816 healthy adults (P = 0.039) and 21 1 (P = 0.038) healthy children, respectively. The low or (Fig. 4) . These observations indicated that the acetylhydrolase activity-negative serum had no effect on 1 X 10-9-5 X 10-4 M PAF. PAF-acetylhydrolase activity was not observed in the deficient serum at the reaction times, serum concentrations and PAF concentrations investigated, as shown in Fig. 2 . Deficiency of PAF acetylhydrolase activity was also observed over the course of 1 d, 1 wk, and several months (Fig. 3) . These results suggested that the undetectable or very low level of PAF acetylhydrolase activity was not due to the presence of its inhibitor and/or a deficiency of enzyme(s) necessary for activating the inactive PAF acetylhydrolase (proenzyme), and that it was the result of a defect of the PAF acetylhydrolase itself.
As it has been reported that serum PAF acetylhydrolase is associated with LDL (36), the levels of LDL, cholesterol, and PAF acetylhydrolase activity in normal and PAF acetylhydrolase-deficient sera were determined. Table II indicates that serum PAF acetylhydrolase activity, LDL cholesterol, and triacylglycerol levels of deficient subjects were not significantly different from those of the normal subjects. The deficiency of PAF acetylhydrolase was not correlated with the levels of LDL or total cholesterol. Whether such PAF target cells as platelets in PAF acetylhydrolase-deficient blood might have reduced the responsiveness to PAF and whether intracellular acetylhydrolase might also have been lacking in persons showing a deficiency of the serum enzyme are indeed pertinent questions. Platelets from normal and deficient subjects were aggregated to almost the same extent by 2 X 10-9-2 X 10-7 M PAF (data not shown). This indicated that PAF acetylhydrolase deficiency was not correlated with the decreased responsiveness of platelets to PAF. As for the latter question, we succeeded in measuring the intracellular PAF acetylhydrolase activity of platelets. Fig. 5 shows that the reaction products from [3H]alkyl-PAF after incubation with platelets from normal and deficient subjects were 1-[3H]alkyl-2-lyso-sn-glycero-3-phosphocholine (31.4%) Normal subjects (20) and PAF acetylhydrolase deficient subjects (20) were selected randomly among 816 healthy adults. Blood from 12-15-h fasted subject was collected for determination of lipid levels. separated on Silica gel G plates using a chloroform/methanol/water (65:35:7, vol/vol/vol) solvent system. The radioactivity was determined using an ultra-high sensitivity TV camera system (ARGUS-00) as described in Methods. PC, l-O-alkyl-2-acyl-sn-glycero-3-phosphocholine; PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine; LysoPAF, l-O-alkyl-sn-glycero-3-phosphocholine. N, normal subject; D, serum PAF acetylhydrolasedeficient subject. and 1-[3H]alkyl-2-acyl-sn-glycero-3-phosphocholine (68.6%). The different procedure we adopted involved the addition of BSA (final concentration, 7 mg/iml) to the incubation mixture to bind ["4C]acetyl-PAF after the reaction. PAF acetylhydrolase activities in platelets from normal and deficient subjects determined by the TCA precipitation and TLC method are compared in Table III To study the genetic linkage of serum PAF acetylhydrolase deficiency, we selected 10 families in which either parent had PAF acetylhydrolase activity-positive serum but the filial relationships consisted of more than one person with PAF acetylhydrolase deficiency. Among a total of 25 children in 10 families, 12 subjects with PAF acetylhydrolase deficiency were observed. On analysis according to the a priori method (37) , the expected number of deficient subjects was 12.20±1.39, which thus agreed with the observed number. This observation strongly suggested that PAF acetylhydrolase deficiency is transmitted as a recessive trait, assuming that the deficiency is genetically controlled. Fig. 6 shows the distributions of serum PAF acetylhydrolase activity in healthy adults and healthy children. Three groups with different levels of serum PAF acetylhydrolase activity (normal, 124/211; low, 79/211, P = 0.374; deficient, 8/211, P = 0.038) were recognized in healthy children. Assuming that PAF acetylhydrolase deficiency is inherited as a recessive trait as described above, the probability ofa subject having heterozygosity (q = 2VP-) is 0.39, since 32 and 8 subjects with PAF acetylhydrolase deficiency (homozygous, P = 0.038) were found among 816 healthy adults and 21 1 healthy children, respectively. The theoretically calculated probability (q) of heterozygosity in children, agreed with the observed probability of subjects with low enzyme activity (low group) in Fig. 6 (79/21 1, P = 0.394). This shows that the subjects, for whom serum PAF acetylhydrolase activity among children was < 1.2 nmol/min per 50 ,l serum (not deficient), may be heterozygous. On the other hand, for adult enzyme activities, neither a bimodal or normal distribution was observed, indicating that the enzyme activity may be genetically controlled, whereas the adult enzyme activity could be complicated by other factors. Fig. 7 shows PAF acetylhydrolase activity in serum from five families, each of which had more than one person with PAF acetylhydrolase deficiency. The subjects with the deficiency of serum PAF acetylhydrolase were healthy in families A (second generation), B (third generation), C (first and second generations), D (first generation), and E (first, second, and third generations), and the second and third generations in family D suffered from acute myelo- :tylhydrolase activity was measured by the 11~~a. *~TCA precipitation method as described in [24] , and severe [ 18] ) on the basis oftheir respiratory symptoms over the previous 2 yr. The lack of variation of serum PAF acetylhydrolase activity at different times, which was shown for healthy adults in Fig. 3 , was also observed among the same patients without asthmatic attacks (data not shown). These patients had not ingested medicine(s) for at least 1 wk before donation except for theophylline and aspirin, which were administered to some of the patients. Administration of theophylline and aspirin to asthmatic children did not affect the enzyme activity (data not shown). PAF acetylhydrolase activity in patients without asthmatic attacks was reduced in the severe group in comparison with the groups showing slight symptoms (remission, wheezy, and mild, P < 0.05, P < 0.1, P < 0.01, respectively) (Fig. 8 ). There were no significant differences between the enzyme activities of the patients with and without asthmatic attacks (data not shown). There were five deficient subjects in the most severe groups (42 subjects in the moderate and severe groups). The probability of occurrence in the most severe group (5/42) was significantly higher (P < 0.01) than those in healthy adults (32/816), healthy children of a similar age (1/36) and in the groups showing slight symptoms (remission, wheezy, and mild groups, 2/133). Next, to explain the effect of asthmatic attacks with airway obstruction on PAF acetylhydrolase activity, a 13-yr-old girl with intolerance to aspirin was investigated. A sublingual challenge with aspirin induced symptoms such as urticaria, angioedema, wheezing, and dyspnea with a decline in peak expiratory flow rate (Fig.  9) . Venous blood samples, which were collected during the challenge, showed a rise in plasma histamine and a decrease in platelet count at the onset of these symptoms (data not shown). However, the serum PAF acetylhydrolase activity did not change (Fig. 9) . Furthermore, the enzyme activities of patients with atopic asthma were not affected by severe attacks (dyspnea) lasting 12 h or more (Fig. 9) .
These observations suggest that the asthmatic patient with deficient and/or low activity of serum PAF acetylhydrolase might tend to have the severe symptoms.
Concluding remarks. The method we developed to measure the radioactivity of the supernatant after precipitation of the complex of radioactive substrate and albumin with TCA was reliable and useful for the routine assay of PAF acetylhydrolase activity (Figs. 1 and 5, and Table III metabolites of PAF such as those in platelets were l-alkyl-2-lyso-sn-glycero-3-phosphocholine and 1-O-alkyl-2-acyl-snglycero-3-phosphocholine, but almost all metabolites in serum were 1-O-alkyl-2-lyso-sn-glycero-3-phosphocholine. The serum PAF acetylhydrolase activity obtained by the TCA precipitation method was similar to that obtained by the TLC method (Fig. 1) . The different Km value (1.5 X l0-' M) from the data (1.37 X l0' M) reported by Stafforini et al. (39) might have been caused by the use of a 250-fold higher concentration of serum, because serum albumin easily binds PAF and this would affect the interaction between PAF and acetylhydrolase (40). To determine the enzyme activity under assay conditions close to the physiological concentration of serum protein, we used a higher concentration of serum in this study, at which the PAF acetylhydrolase activity showed linearity with both time and protein concentration (Fig. 2) . Serum PAF acetylhydrolase is associated with lipoprotein (both low-density and high-density lipoprotein) and is hypothesized to inactivate PAF in order to maintain circulating PAF below harmful levels (26-28, 39, 40) . This paper is the first to describe a deficiency of serum PAF acetylhydrolase, which was independent of the level of LDL and total cholesterol.
To date, there has been no information regarding serum PAF acetylhydrolase production in body organs. PAF acetylhydrolase production is known to occur in tissues (29, 30 ) and blood cells (31) such as neutrophils, eosinophils, and platelets. Intracellular PAF acetylhydrolase plays an important role in metabolizing PAF within the cell (41) (42) (43) (44) (45) . Some differences in enzyme properties between serum and intracellular acetylhydrolase, e.g., substrate specificity, have been reported (29, 46) . The intracellular PAF acetylhydrolase activity even in platelets from subjects with enzyme deficiency was similar to that from normal subjects. These results indicate that serum and intracellular acetylhydrolase might be different proteins with different functions produced by different genes. Studies are currently in progress to explain whether the deficiency of serum PAF acetylhydrolase activity is due to lack of production or degradation of the enzyme, the prevention of its secretion into the blood from the organ of origin or an abnormal distribution or association with lipoprotein of the enzyme.
Serum PAF acetylhydrolase deficiency is apparently transmitted autosomally (Fig. 7) , although a more detailed family study will be needed to clarify the inheritance pattern of this deficiency. It was found that not all subjects with serum PAF acetylhydrolase deficiency had clinically apparent symptoms, for example, asthma, thrombosis and hypertension. The mechanism that protects these persons from PAF accumulation is not known at present.
It would be interesting to explain the correlation of the deficiency of serum PAF acetylhydrolase with some syndromes potentially attributable to excess PAF in view of the hypothesis that PAF may be a humoral mediator in such syndromes. We found that deficiency of serum PAF acetylhydrolase was correlated with the severity of respiratory symptoms of bronchial asthma in elementary school children (Fig. 8) .
Although the capacity to degrade PAF was slightly elevated in atherosclerotic patients (47) , the enzyme activity showed no significant change during asthmatic attacks, which caused a decrease in peak expiratory flow rate (Fig. 9) . Furthermore, the enzyme activities of five severely asthmatic children showed no change during the course of severe attacks (dyspnea) lasting 12 h or more (Fig. 9 ). This shows that PAF acetylhydrolase was not released from inflammatory tissues or cells during asthmatic attacks. Even if acetylhydrolase was released from these cells, it is presumed that the amount of released enzyme would be small and have no direct effects upon the acetylhydrolase level in circulating blood. PAF is a potent lipid mediator that induces pulmonary recruitment of eosinophils (13, 14) and causes platelet-dependent bronchoconstriction and hypersensitivity of the respiratory tract (38, 48) . Acute IgE anaphylaxis in the rabbit has been speculated to occur secondary to the release of PAF (49) . PAF synthesized by stimulated rabbit basophils is released, but many inflammatory cells such as human lung mast cells, endothelial cells, and neutrophils retain almost all of the synthesized PAF (50, 51) . Furthermore, in this study, both the platelet responsiveness to PAF and the intracellular metabolism of PAF were normal even in the subjects who showed deficiency of serum PAF acetylhydrolase ( Fig. 5 and Table III) .
From these observations, we suggest that (a) PAF may be released into the blood only in specific syndromes such as asthma, (b) the action of PAF in blood may be controlled by serum PAF acetylhydrolase or endogenous PAF inhibitor(s) (52) , and (c) an abnormality in the blood PAF level due to deficiency or low activity of serum PAF acetylhydrolase might cause more severe respiratory symptoms in asthmatic children. Further studies will be needed in order to confirm these possibilities.
